Page last updated: 2024-11-02

pioglitazone and Hirsutism

pioglitazone has been researched along with Hirsutism in 8 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Hirsutism: A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.

Research Excerpts

ExcerptRelevanceReference
" PCOS women were treated with pioglitazone 30 mg/day and at the beginning and after 6 months of treatment were evaluated: menstrual cycle trend, hirsutism and acne, total cholesterolemia and HDL, triglyceridemia, fibrinogenemia, C-reactive protein, oral glucose tolerance test, glycated hemoglobin, FSH, LH, 17OH-progesterone, 17β-estradiol, free and total testosterone, SHBG, DHEA-S, Δ4-androstenedione and adiponectin."9.19Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. ( Artenisio, AC; Benvenga, S; Borrielli, I; Bruno, LM; Giunta, L; La Marca, A; Pizzo, A; Stabile, G; Volpe, A, 2014)
"We designed a study, involving 52 patients of 19-36 years of age, to test the pioglitazone in women with polycystic ovary syndrome."9.16Pioglitazone reduces central obesity in polycystic ovary syndrome women. ( Asadipooya, K; Kalantar-Hormozi, M; Nabipour, I, 2012)
"Our results suggest that RBP4 may contribute to endocrine changes and to the phenotypic manifestation of patients with PCOS because higher RBP4 concentrations are associated with higher androgen levels and higher clinical hirsutism scores independently of pioglitazone treatment."9.14Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment. ( Aigner, E; Bachofner, N; Datz, C; De Geyter, C; Hohla, F; Klein, K; Patsch, W, 2009)
"To investigate the effectiveness and safety of pioglitazone (45 mg/day) on clinical and endocrine-metabolic features of polycystic ovary syndrome (PCOS), we studied 18 obese PCOS patients, classified as normoinsulinaemic (N-PCOS, n = 6) and hyperinsulinaemic (H-PCOS, n = 12) according to their insulin secretion."9.10Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. ( Ciampelli, M; Giuliani, M; Guido, M; Lanzone, A; Leoni, F; Perri, C; Romualdi, D, 2003)
"Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)."8.88A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012)
" PCOS women were treated with pioglitazone 30 mg/day and at the beginning and after 6 months of treatment were evaluated: menstrual cycle trend, hirsutism and acne, total cholesterolemia and HDL, triglyceridemia, fibrinogenemia, C-reactive protein, oral glucose tolerance test, glycated hemoglobin, FSH, LH, 17OH-progesterone, 17β-estradiol, free and total testosterone, SHBG, DHEA-S, Δ4-androstenedione and adiponectin."5.19Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. ( Artenisio, AC; Benvenga, S; Borrielli, I; Bruno, LM; Giunta, L; La Marca, A; Pizzo, A; Stabile, G; Volpe, A, 2014)
"We designed a study, involving 52 patients of 19-36 years of age, to test the pioglitazone in women with polycystic ovary syndrome."5.16Pioglitazone reduces central obesity in polycystic ovary syndrome women. ( Asadipooya, K; Kalantar-Hormozi, M; Nabipour, I, 2012)
"Our results suggest that RBP4 may contribute to endocrine changes and to the phenotypic manifestation of patients with PCOS because higher RBP4 concentrations are associated with higher androgen levels and higher clinical hirsutism scores independently of pioglitazone treatment."5.14Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment. ( Aigner, E; Bachofner, N; Datz, C; De Geyter, C; Hohla, F; Klein, K; Patsch, W, 2009)
"To investigate the effectiveness and safety of pioglitazone (45 mg/day) on clinical and endocrine-metabolic features of polycystic ovary syndrome (PCOS), we studied 18 obese PCOS patients, classified as normoinsulinaemic (N-PCOS, n = 6) and hyperinsulinaemic (H-PCOS, n = 12) according to their insulin secretion."5.10Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. ( Ciampelli, M; Giuliani, M; Guido, M; Lanzone, A; Leoni, F; Perri, C; Romualdi, D, 2003)
"Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)."4.88A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ibáñez, L3
Del Río, L1
Díaz, M2
Sebastiani, G1
Pozo, ÓJ1
López-Bermejo, A2
de Zegher, F3
Ong, KK1
Dunger, DB1
Stabile, G1
Borrielli, I1
Artenisio, AC1
Bruno, LM1
Benvenga, S1
Giunta, L1
La Marca, A1
Volpe, A1
Pizzo, A1
Gallego-Escuredo, JM1
Villarroya, F1
Aigner, E1
Bachofner, N1
Klein, K1
De Geyter, C1
Hohla, F1
Patsch, W1
Datz, C1
Asadipooya, K1
Kalantar-Hormozi, M1
Nabipour, I1
Du, Q1
Wang, YJ1
Yang, S1
Wu, B1
Han, P1
Zhao, YY1
Romualdi, D1
Guido, M1
Ciampelli, M1
Giuliani, M1
Leoni, F1
Perri, C1
Lanzone, A1

Reviews

1 review available for pioglitazone and Hirsutism

ArticleYear
A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.
    Current medical research and opinion, 2012, Volume: 28, Issue:5

    Topics: Blood Glucose; Body Mass Index; Female; Hirsutism; Humans; Hyperinsulinism; Insulin Resistance; Metf

2012

Trials

6 trials available for pioglitazone and Hirsutism

ArticleYear
Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
    The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2017, Volume: 61, Issue:4

    Topics: Adolescent; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; F

2017
Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome.
    Journal of pediatric and adolescent gynecology, 2014, Volume: 27, Issue:3

    Topics: Adiponectin; Adolescent; C-Reactive Protein; Female; Fibrinogen; Hirsutism; Humans; Hyperandrogenism

2014
Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.
    Diabetes & metabolism, 2016, Volume: 42, Issue:3

    Topics: Adolescent; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Fibroblast Growth Fac

2016
Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment.
    The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:4

    Topics: Adipokines; Adult; Area Under Curve; Blood Glucose; Double-Blind Method; Female; Hirsutism; Humans;

2009
Pioglitazone reduces central obesity in polycystic ovary syndrome women.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012, Volume: 28, Issue:1

    Topics: Adult; Body Mass Index; Body Weight; Female; Hirsutism; Humans; Hypoglycemic Agents; Intra-Abdominal

2012
Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.
    Human reproduction (Oxford, England), 2003, Volume: 18, Issue:6

    Topics: 17-alpha-Hydroxyprogesterone; Acne Vulgaris; Adolescent; Adult; Androgens; Androstenedione; Body Con

2003

Other Studies

1 other study available for pioglitazone and Hirsutism

ArticleYear
Hyperinsulinaemic androgen excess in adolescent girls.
    Nature reviews. Endocrinology, 2014, Volume: 10, Issue:8

    Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human

2014
chemdatabank.com